---
schema_version: "secwatch.filing_event.v1"
accession: "0001562762-21-000413"
form_type: "8-K"
ticker: "GMED"
cik: "0001237831"
company_name: "GLOBUS MEDICAL INC"
filed_at: "2021-11-04T23:59:59+00:00"
generated_at: "2026-06-28T12:38:48.027925+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Globus Medical Q3 2021 revenue up 6.3% to $229.7M; GAAP EPS $0.45, non-GAAP $0.50; FY guidance reaffirmed

## Summary
- Worldwide net sales $229.7M (+6.3% YoY); US sales +8.8%, International -7.2%.
- GAAP net income $47.2M (20.6% of sales); GAAP diluted EPS $0.45 vs $0.44; non-GAAP diluted EPS $0.50 vs $0.49.
- Non-GAAP adjusted EBITDA $78.3M (34.1% of sales); operating cash flow $77.3M; free cash flow $59.5M.
- Cash, equivalents and marketable securities $985M; debt-free. FY2021 guidance reaffirmed: net sales $950M, non-GAAP diluted EPS $2.00.
- CEO cites market share gains, Enabling Technology momentum, best recruiting quarter, and FDA clearances for Excelsius3D and ExcelsiusHUB.

## SEC filing metadata
- accession: 0001562762-21-000413
- form_type: 8-K
- ticker: GMED
- cik: 0001237831
- company_name: GLOBUS MEDICAL INC
- filed_at: 2021-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1237831/000156276221000413/0001562762-21-000413-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1237831/000156276221000413/gmed-20211104x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001562762-21-000413
- JSON: https://secwatch.observer/filing/0001562762-21-000413.json
- Plain text: https://secwatch.observer/filing/0001562762-21-000413.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.